Giannis Mountzios, Director of the 4th Oncology Department and Clinical Trials Unit at Henry Dunant Hospital Center, shared a post on X:
“With WCLC25 in 1 week, OS data from FLAURA2 in EGFR + NSCLC are eagerly awaited.
Given that mOS in FLAURA was 38.6m and that mOS in MARIPOSA is projected to exceed 4 years, what would you consider convincing OS to prefer FLAURA2 in PS0/1?”
At the end of his post, Giannis Mountzios included a poll asking: “What would you consider convincing OS to prefer FLAURA2 in PS0/1?”
The options were:
- mOS over 45 months
- mOS over 48 months
- Any Better than MARIPOSA
- Other? Please explain!
More posts featuring Giannis Mountzios on OncoDaily.